Oncocyte to Present at the 15th Annual LD Micro Main Event

Rhea-AI Summary

Oncocyte Corporation (NYSE American: OCX) announced its participation in the 13th Annual LD Micro Main Event Conference on December 15, 2020. The company will present from 12:40 PM to 1:00 PM EST. Investors can register for the event online. Following the presentation, a replay will be available on Oncocyte's investor website. Oncocyte focuses on providing actionable diagnostics across the cancer care continuum, with products like DetermaRx™, which identifies high-risk lung cancer patients, and DetermaIO™, assessing tumor responses to immunotherapies.

IRVINE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, announced today that management is scheduled to present at the 13^th Annual LD Micro Main Event Conference.

Presentation details:
Date: Tuesday, December 15, 2020
Time: 12:40 – 1:00PM EST

Investors can register for the conference HERE.
   
Following the conference, a webcast replay of the presentation will be available on the Investor section of the company’s website, www.oncocyte.com.

About Oncocyte Corporation
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company’s tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte recently launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. The Company also plans to launch monitoring tests including Therasure™-CNI MONITOR, a blood-based immune therapy monitoring test, as a research use tool in 2021. Oncocyte’s pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

DetermaRx and DetermaIO are trademarks of Oncocyte Corporation. Therasure is a trademark of Chronix Biomedical Inc.

Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com

Media Contact
Cait Williamson, Ph.D.
LifeSci Communications, LLC
646-751-4366
cait@lifescicomms.com

FAQ

What is Oncocyte Corporation presenting at the LD Micro Conference?

Oncocyte Corporation is presenting at the 13th Annual LD Micro Main Event Conference on December 15, 2020, from 12:40 PM to 1:00 PM EST.

Where can I watch the Oncocyte presentation after the conference?

The Oncocyte presentation will be available for replay on the company's investor website after the conference.

What products does Oncocyte offer for cancer diagnostics?

Oncocyte offers DetermaRx™, which identifies high-risk lung cancer patients, and DetermaIO™, a test to assess tumor responses to immunotherapies.

What is the significance of DetermaRx™ and DetermaIO™?

DetermaRx™ helps in identifying early-stage lung cancer patients at risk for recurrence, while DetermaIO™ predicts responses to immunotherapy, aiding in treatment decisions.

What time is the Oncocyte presentation at the LD Micro Conference?

The Oncocyte presentation is scheduled for December 15, 2020, from 12:40 PM to 1:00 PM EST.